Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263215 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL5390794 | 1.00 | SMN1; SMN2 (0.77) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL7462577 | 0.91 | SMN1; SMN2 (0.65) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL14662009 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL12741625 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL5781007 | 0.85 | POLB (0.68) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL2183180 | 0.85 | POLB (0.68) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL5069460 | 0.85 | POLB (0.68) | SMN1; SMN2HPGDPOLBTP53MEN1 | |
| SCHEMBL1902358 | 0.84 | SMN1; SMN2 (0.76) | SMN1; SMN2HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL2314610 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2POLBTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480977-A2 | SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-01 | — | — | EP | claimed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| WO-2003070728-A2 | AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | claimed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2008157365-A2 | VINYLAZACYCLOALKANES FOR TREATING NEUROPATHIC PAIN | TARGACEPT, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1987034-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007100670-A1 | SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | PFIZER INC | 2006-06-01 | — | — | US | disclosed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| CN-1735441-A | Combination for treating attention deficit hyperactivity disorder | PHARMACIA & UPJOHN CO LLC (US) | 2006-02-15 | — | — | CN | disclosed |
| WO-2003070728-A2 | AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | disclosed |
| WO-2003042210-A1 | AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALPHA7 NACHR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003040147-A1 | AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037896-A1 | N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002096908-A1 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | TPMT, PAICS, MALT1 | SMN1; SMN2 1644/4885HPGD 244/4885POLB 351/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | SMN1; SMN2 1836/4885HPGD 879/4885POLB 307/4885 |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | SMN1; SMN2 446/4885HPGD 794/4885POLB 1866/4885 |
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | CYP7B1, P2RX7, CYP3A7 | SMN1; SMN2 1326/4885HPGD 787/4885POLB 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.